셀트리온제약

068760KOSDAQ

48.0 / 100

Reference Date: 2026-10-23

Financial Score20.5 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Slightly down 1.3% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Celltrion Pharma is a pharmaceutical company with KGMP, U.S. cGMP, and EU-GMP certifications, producing specialty and biopharmaceuticals at facilities in Jincheon and Ochang, South Korea. Key products include the liver disease treatment 'Godeks' and biosimilars such as 'Ramsima', 'Omlizumab', 'Stelizumab', and 'Aducanumab'. Sales in 2024 rose 22.9% year-on-year to 4.778 trillion KRW.

Number of Employees

1,006people

Average Salary

77.2M KRW

Score Calculation Basis

Detailed Financial Score

PER

42.99Industry Average 15.000.0Point

2.9x industry avg (risky)

PBR

3.91Industry Average 1.200.0Point

3.3x industry avg (risky)

ROE

9.31Industry Average 8.004.0Point

In line with industry avg

Debt Ratio

9.14Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20258.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲17.6% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲26.9% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 6.9% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (4%, downtrend)

Current 38,350Won52-week high 75,70052-week low 36,450

1-month return3.0Point

1m -1.29% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0